CRAD B logo

C-Rad AB (publ) Stock Price

OM:CRAD B Community·SEK 1.2b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

CRAD B Share Price Performance

SEK 34.30
1.30 (3.94%)
SEK 30.00
Fair Value
SEK 34.30
1.30 (3.94%)
14.3% overvalued intrinsic discount
SEK 30.00
Fair Value
Price SEK 34.30
AnalystConsensusTarget SEK 30.00

CRAD B Community Narratives

·
Fair Value SEK 30 14.3% overvalued intrinsic discount

Aging Population And Healthcare Digitization Will Expand Radiotherapy Demand

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
SEK 30
14.3% overvalued intrinsic discount
Revenue
7.96% p.a.
Profit Margin
16.51%
Future PE
12.47x
Price in 2029
SEK 35.62

Trending Discussion

Updated Narratives

CRAD B logo

CRAD B: Trimmed Assumptions And 2026 Meeting Will Shape Balanced Outlook

Fair Value: SEK 30 14.3% overvalued intrinsic discount
5 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

0 Risks
2 Rewards

C-Rad AB (publ) Key Details

SEK 427.8m

Revenue

SEK 111.6m

Cost of Revenue

SEK 316.2m

Gross Profit

SEK 286.5m

Other Expenses

SEK 29.8m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 17, 2026
0.88
73.92%
6.96%
0%
View Full Analysis

About CRAD B

Founded
2004
Employees
110
CEO
Tomas Blomquist
WebsiteView website
c-rad.com

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating; and Sentinel 4DCT, a laser-based optical surface scanning system. It also provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; and visual coaching solutions used for prospective and retrospective radiotherapy. In addition, the company offers cAutoVerify, an automation solution for the imaging suite and treatment room, automating patient identity validation, and accessory tracking. Further, it provides HIT1, HIT3, and HIT5 patient positioning laser, as well as laser positioning products and solutions. Additionally, the company offers support and training services; and service contracts. C-Rad AB (publ) was incorporated in 2004 and is headquartered in Uppsala, Sweden.